Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway - Takeaways - MDSpire

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • By

  • Biao Zheng

  • Guojun Yao

  • Yuli Pang

  • Jielong Luo

  • Zhiyong Yang

  • Fengmin Xiu

  • Chaohui Zhen

  • Rui Liang

  • June 9, 2026

  • 0 min

Share

  • 1

    Tetrandrine (TET) significantly inhibits hepatocellular carcinoma (HCC) growth and induces apoptosis.

  • 2

    TET promotes CD8+ T cell activation, proliferation, and cytotoxicity, enhancing their ability to secrete IFN-γ and TNF-α.

  • 3

    TET activates the STING/TBK1/IRF3 signaling pathway, which is crucial for its anti-cancer effects.

  • 4

    The combination of TET and anti-PD-1 therapy produces a significant synergistic anti-tumor effect in HCC models.

  • 5

    No obvious toxic reactions were observed with TET treatment, indicating its potential safety in therapeutic applications.

Original Source(s)

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • by Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang

  • June 9, 2026

Related Content

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review

Impact of clinical pharmacist-led medication management and education on tacrolimus therapeutic control

Editorial: New Insights on Sialic Acid and Sialylated Glycans in the Tumorigenic Process